Mirum Pharmaceuticals MIRM 深 滬
已收盤 07-25 16:00:00 美东时间
51.83
-0.340
-0.65%
華盛通- 最 高52.33
- 今 開52.01
- 成交量 24.78万股
- 最 低 51.22
- 昨 收 52.17
- 總市值 25.67亿
- 52周最高 54.78
- 市盈率 靜 --
- 換手率 0.50%
- 52周最低 36.20
- 委 比 62.10%
- 總股本 4953.47万
- 歷史最高 54.78
- 量 比 0.79
- 振 幅 2.13%
- 歷史最低 6.513
- 每 手 1
- 風險率 4.19%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 摩根大通：维持网易"超配"评级，目标价升至135美元；瑞银上调达美航空评级至"买入"
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1131517965561573377.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• HC Wainwright & Co.：维持Armata Pharmaceuticals(ARMP)"买入"评级，目标价从7美元升至9美元</p> <p>• 瑞银：维持爱芬奇(ANF)"买入"评级，目标价从115美
05-20 09:28
HC Wainwright & Co. Assumes Mirum Pharmaceuticals at Buy, Announces Price Target of $73
HC Wainwright & Co. analyst Swayampakula Ramakanth assumes Mirum Pharmaceuticals (NASDAQ:MIRM) with a Buy rating and announces Price Target of $73.
05-19 19:07
美股大行评级 | 潜在涨幅158.9%！蒙特利尔银行上调Disc Medicine目标价至120美元，维持"跑赢大市"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1129333511617925121.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• 蒙特利尔银行：维持Disc Medicine(IRON)"跑赢大市"评级，目标价从112美元升至120美元</p> <p>• 巴克莱：维持Karyopharm Therapeutics(KPTI)"超配"评级，目标价从5美
05-14 08:48
美股大行评级 | 潜在涨幅754.7%！HC Wainwright & Co.：Alector获机构升目标价至10美元，维持"买入"评级
潜在涨幅754.7%！HC Wainwright & Co.：Alector获机构升目标价至10美元，维持"买入"评级
05-10 10:00
Beyond The Numbers: 4 Analysts Discuss Mirum Pharmaceuticals Stock
Throughout the last three months, 4 analysts have evaluated Mirum Pharmaceutica...
05-10 04:01
Mirum Pharmaceuticals shares are trading higher after the company reported better-than-expected Q1 financial results and raised its FY25 sales guidance above estimates.
Mirum Pharmaceuticals shares are trading higher after the company reported bett...
05-08 22:52
Mirum Pharmaceuticals Raises FY2025 Sales Guidance from $420.00M-$435.00M to $435.00M-$450.00M vs $427.76M Est
Mirum Pharmaceuticals (NASDAQ:MIRM) raises FY2025 sales outlook from $420.00 million-$435.00 million to $435.00 million-$450.00 million vs $427.76 million estimate.
05-08 04:04
Mirum Pharmaceuticals Q1 EPS $(0.30) Beats $(0.32) Estimate, Sales $111.60M Beat $98.40M Estimate
Mirum Pharmaceuticals (NASDAQ:MIRM) reported quarterly losses of $(0.30) per share which beat the analyst consensus estimate of $(0.32) by 6.25 percent. This is a 44.44 percent increase over losses of $(0.54) per share
05-08 04:03
Earnings Scheduled For May 7, 2025
Companies Reporting Before The Bell • Wallbox (NYSE:WBX) is estimated to report...
05-07 16:33
